# IBL Data Sheet

Code No. 18163

**Anti-Human**
**FHIT (F130) Rabbit IgG Affinity Purify**

Volume : 100 µg

Lot No. :

**Introduction** : A candidate tumor suppressor gene, *FHIT* (Fragile Histidine Triad), was indicated at chromosome 3p14.2 spanning the FRA3B common fragile site. Abnormalities in structure and expression of the *FHIT* gene have been detected in a considerable fraction of lung tumors of small and non-small cell types. There are several reports on the correlations between abnormalities of the *FHIT* gene and clinicopathological features in lung cancer.

**Antigen** : Synthetic peptide of the C terminal part of Human FHIT

**Purification** : Purified with antigen peptide

**Form** : Lyophilized product from 1 % BSA in PBS containing 0.05% $NaN_3$

**How to use** : 1.0 mL deionized water will be added to the product (the conc. comes up 100 µg /mL)

**Stability** : Lyophilized product, 5 years at 2 – 8 °C
: Solution, 2 years at –20 °C

**Application** : This antibody can be used for immunohistochemistry with formalin fixed paraffin embedded tissues after microwave pretreatment by several techniques such as Avidin Biotin Complex (ABC) Method. The optimal concentration is 2-5 µg/mL, however, the concentration should be optimized by each laboratory.
: This antibody can be used for western blotting in concentration of 5 µg /mL.

**Specificity** : The specific was confirmed against various human cell lines and peripheral blood lymphocyte by WB, and against various human normal tissue by IHC.

**Reference** : 1. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, and Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res. 1998: 58 (23), 5478-5483.



Distributed by:

Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246
Email: info@IBL-America.com
Web: www.IBL-America.com

Immuno-Biological
Laboratories Co., Ltd.